PD-1 and its ligands in tolerance and immunity

Annual Review of Immunology

Volumn 26, Issue , 2008, Pages 677-704

  Keir, Mary E ^a   Butte, Manish J ^a   Freeman, Gordon J ^b,c   Sharpe, Arlene H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Autoimmunity; Costimulation; Infectious disease; T cell; Tumor

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PD 1; MONOCLONAL ANTIBODY PD L1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN PD 1; PROTEIN PD L1; PROTEIN PD L2; PROTEIN TYROSINE PHOSPHATASE SHP 2; T LYMPHOCYTE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ALLERGY; ANTIGEN PRESENTING CELL; ASTHMA; AUTOIMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION; LIGAND BINDING; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; APOPTOSIS REGULATORY PROTEINS; HUMANS; IMMUNITY; LIGANDS; MODELS, IMMUNOLOGICAL; SELF TOLERANCE;

EID: 42649125225     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.26.021607.090331     Document Type: Review

References (154)

1. Lafferty KJ, Cunningham AJ. 1975. A new analysis of allogeneic interactions. Aust. J. Exp. Biol. Med. Sci. 53:27-42
2. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-47
3. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, et al. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-88
4. Ishida Y, Agata Y, Shibahara K, Honjo T. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887-95
5. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-51
6. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, et al. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319-22
7. Dong H, Zhu G, Tamada K, Chen L. 1999. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5:1365-69
8. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027-34
9. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2:261-68
10. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, et al. 2001. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193:839-46
11. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27:111-22
12. Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. 2005. Alternative splice variants of the human PD-1 gene. Cell. Immunol. 235:109-16
13. Ueda H, Howson JM, Esposito L, Heward J, Snook H, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-11
14. Wan B, Nie H, Liu A, Feng G, He D, et al. 2006. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177:8844-50
15. He XH, Xu LH, Liu Y. 2005. Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain. Acta Pharmacol. Sin. 26:462-68
16. He XH, Liu Y, Xu LH, Zeng YY. 2004. Cloning and identification of two novel splice variants of human PD-L2. Acta Biochim. Biophys. Sin. 36:284-89
17. Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L. 2003. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J. Exp. Med. 197:1083-91
18. Zhang X, Schwartz JC, Guo X, Bhatia S, Cao E, et al. 2004. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20:337-47
19. -) thymocytes. Int. Immunol. 8:773-80
20. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173:945-54
21. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, et al. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8:765-72
22. + resting regulatory T cells from activated T cells. J. Immunol. 176:2808-16
23. Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP. 2007. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc. Natl. Acad. Sci. USA 104:17765-70
24. + T cell survival in HIV infection. J. Exp. Med. 203:2281-92
25. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, et al. 2002. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169:5538-45
26. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, et al. 2002. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 9:133-45
27. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, et al. 2004. Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J. Neuroimmunol. 155:172-82
28. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, et al. 2006. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett. 580:755-62
29. Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, et al. 2007. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110:296-304
30. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, et al. 2007. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13:84-88
31. H12 and phosphatidylcholine binding. Eur. J. Immunol. 37:2405-10
32. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, et al. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33:2706-16
33. Loke P, Allison JP. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100:5336-41
34. + T cells and is overcome by IL-2. Eur. J. Immunol. 32:634-43
35. Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, et al. 2006. T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J. 25:2623-33
36. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, et al. 2004. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ. FEBS Lett. 574:37-41
37. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. 2001. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA 98:13866-71
38. Bennett F, Luxenberg D, Ling V, Wang LM, Marquette K, et al. 2003. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J. Immunol. 170:711-18
39. Egen JG, Allison JP. 2002. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16:23-35
40. Saunders PA, Hendrycks VR, Lidinsky WA, Woods ML. 2005. PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion. Eur. J. Immunol. 35:3561-69
41. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25:9543-53
42. Shlapatska LM, Mikhalap SV, Berdova AG, Zelensky OM, Yun TJ, et al. 2001. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J. Immunol. 166:5480-87
43. Arnaud M, Crouin C, Deon C, Loyaux D, Bertoglio J. 2004. Phosphorylation of Grb2-associated binder 2 on serine 623 by ERK MAPK regulates its association with the phosphatase SHP-2 and decreases STAT5 activation. J. Immunol. 173:3962-71
44. Van Parijs L, Refaeli Y, Lord JD, Nelson BH, Abbas AK, Baltimore D. 1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11:281-88
45. Nguyen LT, Radhakrishnan S, Ciric B, Tamada K, Shin T, et al. 2002. Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J. Exp. Med. 196:1393-98
46. Radhakrishnan S, Nguyen LT, Ciric B, Ure DR, Zhou B, et al. 2003. Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. J. Immunol. 170:1830-38
47. Radhakrishnan S, Nguyen LT, Ciric B, Flies D, Van Keulen VP, et al. 2004. Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity. Cancer Res. 64:4965-72
48. Heckman KL, Schenk EL, Radhakrishnan S, Pavelko KD, Hansen MJ, Pease LR. 2007. Fast-tracked CTL: rapid induction of potent antitumor killer T cells in situ. Eur. J. Immunol. 37:1827-35
49. Radhakrishnan S, Iijima KJ, Kobayashi T, Rodriguez M, Kita H, Pease LR. 2004. Blockade of allergic airway inflammation following systemic treatment with a B7-dendritic cell (PD-L2) cross-linking human antibody. J. Immunol. 173:1360-65
50. Radhakrishnan S, Iijima K, Kobayashi T, Kita H, Pease LR. 2005. Dendritic cells activated by cross-linking B7-DC (PD-L2) block inflammatory airway disease. J. Allergy Clin. Immunol. 116:668-74
51. Van Keulen VP, Ciric B, Radhakrishnan S, Heckman KL, Mitsunaga Y, et al. 2006. Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12. Clin. Exp. Immunol. 143:314-21
52. + T cell activation. Eur. J. Immunol. 36:2472-82
53. Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, et al. 2003. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J. Clin. Invest. 111:363-70
54. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, et al. 2004. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 101:10691-96
55. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, et al. 2003. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9:1477-83
56. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, et al. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170:1257-66
57. Nishimura H, Honjo T, Minato N. 2000. Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J. Exp. Med. 191:891-98
58. Keir ME, Latchman YE, Freeman GJ, Sharpe AH. 2005. Programmed death-1 (PD-1): PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J. Immunol. 175:7372-79
59. Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. 2003. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J. Immunol. 171:4574-81
60. Zucchelli S, Holler P, Yamagata T, Roy M, Benoist C, Mathis D. 2005. Defective central tolerance induction in NOD mice: genomics and genetics. Immunity 22:385-96
61. + T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6:280-86
62. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, et al. 2003. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198:63-69
63. -/- mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. USA 102:11823-28
64. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, et al. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203:883-95
65. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, et al. 2006. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203:2737-47
66. + T cell mediated injury in the heart. Circulation 116:2062-71
67. Keir ME, Freeman GJ, Sharpe AH. 2007. PD-1 regulates self-antigen specific responses in lymph nodes and tissues. J. Immunol. 179:5064-70
68. Cheng X, Zhao Z, Ventura E, Gran B, Shindler KS, Rostami A. 2007. The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-γ. J. Neuroimmunol. 185:75-86
69. Magnus T, Schreiner B, Korn T, Jack C, Guo H, et al. 2005. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J. Neurosci. 25:2537-46
70. Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, et al. 2003. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198:71-78
71. Zhu B, Guleria I, Khosroshahi A, Chitnis T, Imitola J, et al. 2006. Differential role of programmed death-ligand 1 and programmed death-ligand 2 in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J. Immunol. 176:3480-89
72. Carter LL, Leach MW, Azoitei ML, Cui J, Pelker JW, et al. 2007. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 182:124-34
73. + regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found. Symp. 252:67-88
74. + regulatory T cells. J. Immunol. 175:6265-70
75. + T cells. Eur. J. Immunol. 35:1773-85
76. + NKT cells induce the death of colitis-associated cells: involvement of programmed death ligand-1. Eur. J. Immunol. 36:1210-21
77. Okazaki T, Honjo T. 2007. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19:813-24
78. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, et al. 2002. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet 32:666-69
79. Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, et al. 2005. APD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann. Neurol. 58:50-57
80. Thorburn CM, Prokunina-Olsson L, Sterba KA, Lum RF, Seldin MF, et al. 2007. Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. Genes Immun. 8:279-87
81. Wang SC, Lin CH, Ou TT, Wu CC, Tsai WC, et al. 2007. Ligands for programmed cell death 1 gene in patients with systemic lupus erythematosus. J. Rheumatol. 34:721-25
82. Yadav D, Fine C, Azuma M, Sarvetnick N. 2007. B7-1 mediated costimulation regulates pancreatic autoimmunity. Mol. Immunol. 44:2616-24
83. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, et al. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145-55
84. Hirata S, Senju S, Matsuyoshi H, Fukuma D, Uemura Y, Nishimura Y. 2005. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRML or programmed death-1 ligand. J. Immunol. 174:1888-97
85. Ding H, Wu X, Wu J, Yagita H, He Y, et al. 2006. Delivering PD-1 inhibitory signal concomitant with blocking ICOS costimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin. Immunol. 118:258-67
86. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T. 2003. PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198:39-50
87. Jun H, Seo SK, Jeong HY, Seo HM, Zhu G, et al. 2005. B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK). FEBS Lett. 579:6259-64
88. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-87
89. Wherry EJ, Ahmed R. 2004. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78:5535-45
90. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-54
91. + T cells leads to reversible immune dysfunction. Nat. Med. 12:1198-202
92. + T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J. Virol. 80:3532-40
93. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, et al. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81:4215-25
94. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, et al. 2006. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 80:11398-403
95. Chen L, Zhang Z, Chen W, Zhang Z, Li Y, et al. 2007. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol. 178:6634-41
96. + monocytes of patients with chronic hepatitis B virus infection, which correlates with higher serum IL-10 levels. J. Viral Hepat. 13:725-33
97. Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, et al. 2003. B7-H1 is upregulated in HIV infection and is a novel surrogate marker of disease progression. Blood 101:2514-20
98. Velu V, Kannanganat S, Ibegbu C, Chennareddi L, Villinger F, et al. 2007. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J. Virol. 81:5819-28
99. Yao ZQ, King E, Prayther D, Yin D, Moorman J. 2007. T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling. Viral Immunol. 20:276-87
100. + T cells is driven by viral replication and associated with T cell dysfunction. J. Immunol. 179:1979-87
101. + T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 109:4671-78
102. Das S, Suarez G, Beswick EJ, Sierra JC, Graham DY, Reyes VE. 2006. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J. Immunol. 176:3000-9
103. + regulatory T cells. Infect. Immun. 75:4334-41
104. Terrazas LI, Montero D, Terrazas CA, Reyes JL, Rodriguez-Sosa M. 2005. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis. Int. J. Parasitol. 35:1349-58
105. Smith P, Walsh CM, Mangan NE, Fallon RE, Sayers JR, et al. 2004. Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages. J. Immunol. 173:1240-48
106. Liang SC, Greenwald RJ, Latchman YE, Rosas L, Satoskar A, et al. 2006. PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur. J. Immunol. 36:58-64
107. Clarkson MR, Sayegh MH. 2005. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 80:555-63
108. Vadivel N, Trikudanathan S, Chandraker A. 2007. Transplant tolerance through costimulation blockade - are we there yet? Front. Biosci. 12:2935-46
109. Kean LS, Gangappa S, Pearson TC, Larsen CP. 2006. Transplant tolerance in nonhuman primates: progress, current challenges and unmet needs. Am. J. Transplant. 6:884-93
110. Sandner SE, Clarkson MR, Salama AD, Sanchez-Fueyo A, Domenig C, et al. 2005. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J. Immunol. 174:3408-15
111. Tao R, Wang L, Han R, Wang T, Ye Q, et al. 2005. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J. Immunol. 175:5774-82
112. Ozkaynak E, Wang L, Goodearl A, McDonald K, Qin S, et al. 2002. Programmed death-1 targeting can promote allograft survival. J. Immunol. 169:6546-53
113. Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, et al. 2005. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J. Immunol. 174:6648-56
114. Hori J, Wang M, Miyashita M, Tanemoto K, Takahashi H, et al. 2006. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J. Immunol. 177:5928-35
115. Selenko-Gebauer N, Majdic O, Szekeres A, Hofler G, Guthann E, et al. 2003. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J. Immunol. 170:3637-44
116. Abe M, Wang Z, de Creus A, Thomson AW. 2005. Plasmacytoid dendritic cell precursors induce allogeneic T-cell hyporesponsiveness and prolong heart graft survival. Am. J. Transplant. 5:1808-19
117. Tanaka K, Albin MJ, Yuan X, Yamaura K, Habicht A, et al. 2007. PD-L1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J. Immunol. 179:5204-10
118. Koga N, Suzuki J, Kosuge H, Haraguchi G, Onai Y, et al. 2004. Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. Arterioscler. Thromb. Vasc. Biol. 24:2057-62
119. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, et al. 2003. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J. Immunol. 171:1272-77
120. + regulatory T-cell activity to suppress alloimmune responses. Transplantation 83:774-82
121. Matsumoto K, Inoue H, Nakano T, Tsuda M, Yoshiura Y, et al. 2004. B7-DC regulates asthmatic response by an IFN-γ-dependent mechanism. J. Immunol. 172:2530-41
122. Oflazoglu E, Swart DA, Anders-Bartholo P, Jessup HK, Norment AM, et al. 2004. Paradoxical role of programmed death-1 ligand 2 in Th2 immune responses in vitro and in a mouse asthma model in vivo. Eur. J. Immunol. 34:3326-36
123. Fukushima A, Yamaguchi T, Azuma M, Yagita H, Ueno H. 2006. Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice. Br. J. Ophthalmol. 90:1040-45
124. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793-800
125. + T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 104:3360-65
126. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, et al. 2003. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63:6501-5
127. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, et al. 2007. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109:1499-505
128. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. 2004. B7-H1 expression on nonsmall cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 10:5094-100
129. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. 2007. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56:1173-82
130. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, et al. 2007. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13:2151-57
131. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, et al. 2004. Costimulatory B-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. USA 101:17174-79
132. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. 2006. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 108:19-24
133. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard RD, et al. 2003. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp. Med. 198:851-62
134. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. 2006. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 30:802-10
135. + T cells in Hodgkin's lymphoma. Blood 110:3226-33
136. + T-cells in adult T-cell leukemia/lymphoma. Int. J. Cancer 121:2585-90
137. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65:1089-96
138. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99:12293-97
139. Iwai Y, Terawaki S, Honjo T. 2005. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17:133-44
140. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562-67
141. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, et al. 2007. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117:2570-82
142. Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, et al. 2007. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int. Immunol. 19:1223-34
143. Webster WS, Thompson RH, Harris KJ, Frigola X, Kuntz S, et al. 2007. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J. Immunol. 179:2860-69
144. + T cell activation and cytolysis. Eur. J. Immunol. 33:3117-26
145. Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. 2007. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J. Clin. Invest. 117:2974-82
146. Mueller SN, Matloubian M, Clemens DM, Sharpe AH, Freeman GJ, et al. 2007. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc. Natl. Acad. Sci. USA 104:15430-35
147. Iwai Y, Okazaki T, Nishimura H, Kawasaki A, Yagita H, Honjo T. 2002. Microanatomical localization of PD-1 in human tonsils. Immunol. Lett. 83:215-20
148. Tsuda M, Matsumoto K, Inoue H, Matsumura M, Nakano T, et al. 2005. Expression of B7-H1 and B7-DC on the airway epithelium is enhanced by double-stranded RNA. Biochem. Biophys. Res. Commun. 330:263-70
149. Mataki N, Kikuchi K, Kawai T, Higashiyama M, Okada Y, et al. 2007. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. Am. J. Gastroenterol. 102:302-12
150. Mazanet MM, Hughes CC. 2002. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169:3581-88
151. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, et al. 2006. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 176:2238-48
152. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, et al. 2005. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35:1482-90
153. English K, Barry FP, Field-Corbett CP, Mahon BP. 2007. IFN-γ and TNF-α differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 110:91-100
154. Genomics Institute of the Novartis Research Foundation. Online database. GNF SymAtlas v1.2.4. http://expression.gnf.org